MSOP 性质
| 沸点 | 454.0±55.0 °C(Predicted) |
|---|---|
| 密度 | 1.681±0.06 g/cm3(Predicted) |
| 储存条件 | Store at RT |
| 溶解度 | 在水中的溶解度为性3mg/mL，澄清（加热） |
| 形态 | 粉末 |
| 酸度系数(pKa) | 1.66±0.10(Predicted) |
| 颜色 | 白色至米色 |
| 水溶解性 | Soluble to 100 mM in water |
MSOP 用途与合成方法
K D : 51 μM (L-AP4-sensitive presynaptic mGluR).
In the presence of 200 μM MSOP, a rightward parallel shift of the dose-response curve to L-AP4 is observed, with an apparent K D calculated as 51±6 μM (n=3). MSOP is shown to be selective for the L-APC sensitive presynaptic mGluR, the apparent K D for the interaction of MSOP with the (1S, 3S)-ACPD sensitive receptor calculated as greater than 700 μM (n=3).
It is found that TBOA-induced antinociceptive effects are significantly blocked by intrathecal co-administration of MSOP (second phase of formalin model: F 3,16 =30.96, P<0.001; CFA model: F 3,16 =30.77, P<0.001). As expected, intrathecal TBOA (10 μg) reduces the number of formalin-induced flinches and shakes by 47% of the value in the saline-treated group in the second phase (P<0.001) and blocked the CFA-induced decrease in ipsilateral paw withdrawal latency by 60% of the value in the saline-treated group (P=0.01). The number of formalin-induced flinches in the second phase in the group treated with MSOP and TBOA is increased by 56% (P=0.04) of the value in the TBOA-treated group. CFA-induced paw withdrawal latency in the group treated with MSOP and TBOA is decreased by 86% (P=0.03) of the value in the TBOA-treated group.
MSOP 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-04-30 | HY-101226 | 1 mg | 1400 | ||
| 2024-04-30 | HY-101226 | MSOP | 66515-29-5 | 5mg | 2900 |
